Rain Therapeutics Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer
September 08 2021 - 8:00AM
Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage
company developing precision oncology therapeutics, today announced
non-clinical data on its oral mouse double minute 2 (“MDM2”)
inhibitor, milademetan (RAIN-32), presented at the IASLC 2021 World
Conference on Lung Cancer (#WCLC21) hosted by the International
Association for the Study of Lung Cancer and held virtually
September 8-14, 2021.
Key findings from Rain’s poster presentation include:
- Milademetan treatment showed
differential sensitivity in mesothelioma models with cyclin
dependent kinase inhibitor 2A (CDKN2A) loss and wild-type p53
compared to p53 deficient models.
- Milademetan treatment increased p53
protein levels in the MDM2 inhibitor-sensitive cell lines,
demonstrating target engagement and a p53-mediated mechanism of
action.
- Oral milademetan significantly
reduced the growth of multiple MDM2 inhibitor-sensitive MPM
xenografts.
“MPM is an attractive target for MDM2 inhibition given the
genetic profile of simultaneous low p53 mutation rate and high rate
of CDKN2A loss via genetic deletion and other mechanisms,” said
Robert Doebele, M.D., Ph.D., co-founder and chief scientific
officer of Rain. “There is an unmet medical need in MPM patients
after progressing on anti-PD1-based immunotherapies or cytotoxic
agents, and this provides a potential opportunity for a targeted
therapeutic strategy with milademetan in this setting.”
A copy of the presentation will be available by visiting the
“Events & Presentations” section of the Rain website after the
conclusion of the conference and will be archived on the Rain
website for 30 days.
About Milademetan Milademetan is a small
molecule, oral inhibitor of MDM2, which is oncogenic in numerous
cancers. Milademetan has already demonstrated meaningful antitumor
activity in an MDM2-amplified subtype of liposarcoma (“LPS”) and
other solid tumors in a Phase 1 clinical trial, validating a
rationally-designed dosing schedule to mitigate safety concerns and
widen the therapeutic window of MDM2 inhibition. In addition to the
ongoing Phase 3 clinical trial evaluating milademetan in patients
with LPS, Rain Therapeutics anticipates commencing a Phase 2
tumor-agnostic basket trial in certain solid tumors in the second
half of 2021 and a Phase 2 trial in intimal sarcoma by early 2022.
Milademetan has received U.S. Food and Drug Administration Orphan
Drug Designation for patients with LPS.
About Rain Therapeutics Inc.Rain Therapeutics
Inc. is a late-stage precision oncology company developing
therapies that target oncogenic drivers for which it is able to
genetically select patients it believes will most likely benefit.
This approach includes using a tumor-agnostic strategy to select
patients based on their tumors’ underlying genetics rather than
histology. Rain’s lead product candidate, milademetan, is a small
molecule, oral inhibitor of MDM2, which is oncogenic in numerous
cancers. In addition to milademetan, Rain is also developing a
preclinical program that is focused on inducing synthetic lethality
in cancer cells by inhibiting RAD52.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements regarding, among
other things, the results, conduct, progress and timing of Rain’s
ongoing and planned trials for milademetan, the opportunity for
milademetan in MPM patients and the sensitivity and efficacy of
milademetan. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “plans,” “will,” “anticipates,” “goal,” “potential” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Rain’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, risks and uncertainties associated with Rain’s business
in general, our substantial dependence on the success of its lead
product candidate, lack of success in its clinical trials,
difficulties in enrolling patients, competition from competing
products, the impact of the COVID-19 pandemic, and the other risks
and uncertainties described in Rain’s Quarterly Report on Form 10-Q
for the quarter ended June 30, 2021 and subsequent filings with the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made and are based on management’s assumptions and
estimates as of such date. Rain undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made, except as required by
law.
Media ContactJordyn TemperatoLifeSci
Communications+1.646.876.5196jtemperato@lifescicomms.com
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Apr 2023 to Apr 2024